Literature DB >> 23670542

The physical anthropometry, lifestyle habits and blood pressure of people presenting with a first clinical demyelinating event compared to controls: the Ausimmune study.

Anne-Louise Ponsonby1, Robyn M Lucas, Keith Dear, Ingrid van der Mei, Bruce Taylor, Caron Chapman, Alan Coulthard, Terence Dwyer, Trevor J Kilpatrick, Anthony J McMichael, Michael P Pender, Patricia C Valery, David Williams.   

Abstract

INTRODUCTION: Lifestyle factors prior to a first clinical demyelinating event (FCD), a disorder often preceding the development of clinically definite multiple sclerosis (MS), have not previously been examined in detail. Past tobacco smoking has been consistently associated with MS.
METHODS: This was a multicentre incident case-control study. Cases (n = 282) were aged 18-59 years with an FCD and resident within one of four Australian centres (from latitudes 27°S to 43°S), from 1 November 2003 to 31 December 2006. Controls (n = 558) were matched to cases on age, sex and study region, without CNS demyelination. Exposures measured included current and past tobacco and marijuana, alcohol and beverage use, physical activity patterns, blood pressure and physical anthropometry.
RESULTS: A history of smoking ever was associated with FCD risk (AOR 1.89 (95%CL 1.82, 3.52)). Marijuana use was not associated with FCD risk after adjusting for confounders such as smoking ever but the estimates were imprecise because of a low prevalence of use. Alcohol consumption was common and not associated with FCD risk. No case-control differences in blood pressure or physical anthropometry were observed.
CONCLUSIONS: Past tobacco smoking was positively associated with a risk of FCD but most other lifestyle factors were not. Prevention efforts against type 2 diabetes and cardiovascular disease by increasing physical activity and reducing obesity are unlikely to alter MS incidence, and more targeted campaigns will be required.

Entities:  

Keywords:  Multiple sclerosis; demyelination; lifestyle; marijuana; obesity; tobacco

Mesh:

Substances:

Year:  2013        PMID: 23670542     DOI: 10.1177/1352458513483887

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  8 in total

Review 1.  Exercise as Medicine in Multiple Sclerosis-Time for a Paradigm Shift: Preventive, Symptomatic, and Disease-Modifying Aspects and Perspectives.

Authors:  Ulrik Dalgas; Martin Langeskov-Christensen; Egon Stenager; Morten Riemenschneider; Lars G Hvid
Journal:  Curr Neurol Neurosci Rep       Date:  2019-11-13       Impact factor: 5.081

2.  Total Dairy Consumption Is Not Associated With Likelihood of a First Clinical Diagnosis of Central Nervous System Demyelination.

Authors:  Dao Ying Rachel Dieu; Eleanor Dunlop; Alison Daly; Robyn M Lucas; Yasmine Probst; Lucinda J Black
Journal:  Front Neurol       Date:  2022-05-13       Impact factor: 4.086

3.  Estimation of the marginal effect of regular drug use on multiple sclerosis in the Iranian population.

Authors:  Ibrahim Abdollahpour; Saharnaz Nedjat; Mohammad Ali Mansournia; Tibor Schuster
Journal:  PLoS One       Date:  2018-04-24       Impact factor: 3.240

Review 4.  Modifiable risk factors for poor health outcomes in multiple sclerosis: The urgent need for research to maximise smoking cessation success.

Authors:  Claudia H Marck; Roshan das Nair; Lisa B Grech; Ron Borland; Cris S Constantinescu
Journal:  Mult Scler       Date:  2019-06-20       Impact factor: 6.312

5.  Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis.

Authors:  Steve Simpson-Yap; Edward De Brouwer; Tomas Kalincik; Nick Rijke; Jan A Hillert; Clare Walton; Gilles Edan; Yves Moreau; Tim Spelman; Lotte Geys; Tina Parciak; Clement Gautrais; Nikola Lazovski; Ashkan Pirmani; Amin Ardeshirdavanai; Lars Forsberg; Anna Glaser; Robert McBurney; Hollie Schmidt; Arnfin B Bergmann; Stefan Braune; Alexander Stahmann; Rodden Middleton; Amber Salter; Robert J Fox; Anneke van der Walt; Helmut Butzkueven; Raed Alroughani; Serkan Ozakbas; Juan I Rojas; Ingrid van der Mei; Nupur Nag; Rumen Ivanov; Guilherme Sciascia do Olival; Alice Estavo Dias; Melinda Magyari; Doralina Brum; Maria Fernanda Mendes; Ricardo N Alonso; Richard S Nicholas; Johana Bauer; Aníbal Sebastián Chertcoff; Anna Zabalza; Georgina Arrambide; Alexander Fidao; Giancarlo Comi; Liesbet Peeters
Journal:  Neurology       Date:  2021-10-05       Impact factor: 9.910

Review 6.  The adenosinergic signaling in the pathogenesis and treatment of multiple sclerosis.

Authors:  Eduardo Duarte-Silva; Henning Ulrich; Ágatha Oliveira-Giacomelli; Hans-Peter Hartung; Sven G Meuth; Christina Alves Peixoto
Journal:  Front Immunol       Date:  2022-07-28       Impact factor: 8.786

7.  Sun Exposure across the Life Course Significantly Modulates Early Multiple Sclerosis Clinical Course.

Authors:  Steve Simpson; Ingrid van der Mei; Robyn M Lucas; Anne-Louise Ponsonby; Simon Broadley; Leigh Blizzard; Bruce Taylor
Journal:  Front Neurol       Date:  2018-02-01       Impact factor: 4.003

8.  Onset Symptoms, Tobacco Smoking, and Progressive-Onset Phenotype Are Associated With a Delayed Onset of Multiple Sclerosis, and Marijuana Use With an Earlier Onset.

Authors:  Chunrong Tao; Steve Simpson; Bruce V Taylor; Leigh Blizzard; Robyn M Lucas; Anne-Louise Ponsonby; Simon Broadley; Ingrid van der Mei
Journal:  Front Neurol       Date:  2018-06-08       Impact factor: 4.003

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.